[go: up one dir, main page]

SG11201704651UA - Pyridazinone macrocycles as irak inhibitors and uses thereof - Google Patents

Pyridazinone macrocycles as irak inhibitors and uses thereof

Info

Publication number
SG11201704651UA
SG11201704651UA SG11201704651UA SG11201704651UA SG11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA
Authority
SG
Singapore
Prior art keywords
macrocycles
pyridazinone
irak inhibitors
irak
inhibitors
Prior art date
Application number
SG11201704651UA
Inventor
Xiaoling Chen
Ruoxi Lan
Catherine Jorand-Lebrun
Henry Yu
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201704651UA publication Critical patent/SG11201704651UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
SG11201704651UA 2015-02-06 2016-02-05 Pyridazinone macrocycles as irak inhibitors and uses thereof SG11201704651UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562112793P 2015-02-06 2015-02-06
PCT/US2016/016708 WO2016127024A1 (en) 2015-02-06 2016-02-05 Pyridazinone macrocycles as irak inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SG11201704651UA true SG11201704651UA (en) 2017-07-28

Family

ID=55436166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704651UA SG11201704651UA (en) 2015-02-06 2016-02-05 Pyridazinone macrocycles as irak inhibitors and uses thereof

Country Status (14)

Country Link
US (2) US9624246B2 (en)
EP (1) EP3253763B1 (en)
JP (1) JP6920202B2 (en)
KR (1) KR102551597B1 (en)
CN (1) CN107428765B (en)
AU (1) AU2016215184B2 (en)
BR (1) BR112017014970B1 (en)
CA (1) CA2970550C (en)
ES (1) ES2841452T3 (en)
IL (1) IL253519B (en)
MX (1) MX380929B (en)
RU (1) RU2708066C2 (en)
SG (1) SG11201704651UA (en)
WO (1) WO2016127024A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970550C (en) * 2015-02-06 2023-09-19 Merck Patent Gmbh Pyridazinone macrocycles as irak inhibitors and uses thereof
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc Perulo derivatives [1, 2-b] pyridazine
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
WO2019120267A1 (en) * 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 Imidazo[1,2-b]pyridazine macrocyclic kinase inhibitor
MX2020009234A (en) * 2018-04-05 2020-10-12 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof.
TWI842978B (en) 2018-07-13 2024-05-21 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
JP7169429B2 (en) 2018-08-13 2022-11-10 ギリアード サイエンシーズ, インコーポレイテッド Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors
TWI727392B (en) 2018-08-13 2021-05-11 美商基利科學股份有限公司 Thiadiazole irak4 inhibitors
KR102659550B1 (en) 2018-08-13 2024-04-23 길리애드 사이언시즈, 인코포레이티드 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors
US11998534B2 (en) * 2020-02-12 2024-06-04 Eubulus Biotherapeutics Inc. GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
CN111603471B (en) * 2020-06-24 2021-07-09 山东省科学院生物研究所 Use of an o-diaza heterocyclic compound in the preparation of a medicine for inhibiting TLR4 receptors
WO2022070287A1 (en) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 Macrocycle compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000247959A (en) * 1999-02-26 2000-09-12 Kowa Co Pyridazin-3-one derivatives and pharmaceuticals containing the same
JP2010138073A (en) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd Picolinic acid amide compound
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9586948B2 (en) * 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
LT2953952T (en) * 2013-02-07 2017-08-25 Merck Patent Gmbh Macrocyclic pyridazinone derivatives
RS56331B1 (en) * 2013-02-07 2017-12-29 Merck Patent Gmbh Pyridazinone-amides derivatives
CA2970550C (en) * 2015-02-06 2023-09-19 Merck Patent Gmbh Pyridazinone macrocycles as irak inhibitors and uses thereof

Also Published As

Publication number Publication date
IL253519A0 (en) 2017-09-28
AU2016215184A1 (en) 2017-06-29
CA2970550C (en) 2023-09-19
MX2017009624A (en) 2017-11-20
IL253519B (en) 2021-01-31
KR102551597B1 (en) 2023-07-05
EP3253763B1 (en) 2020-09-30
US9624246B2 (en) 2017-04-18
ES2841452T3 (en) 2021-07-08
HK1246287A1 (en) 2018-09-07
NZ732527A (en) 2022-03-25
US20170173019A1 (en) 2017-06-22
RU2017130761A (en) 2019-03-06
CN107428765B (en) 2020-12-29
US20160229871A1 (en) 2016-08-11
MX380929B (en) 2025-03-12
RU2708066C2 (en) 2019-12-04
WO2016127024A1 (en) 2016-08-11
RU2017130761A3 (en) 2019-07-17
KR20170113551A (en) 2017-10-12
JP2018505166A (en) 2018-02-22
CA2970550A1 (en) 2016-08-11
US10517872B2 (en) 2019-12-31
CN107428765A (en) 2017-12-01
BR112017014970A2 (en) 2018-03-27
BR112017014970B1 (en) 2022-11-16
EP3253763A1 (en) 2017-12-13
JP6920202B2 (en) 2021-08-18
AU2016215184B2 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL265922A (en) Tyk2 inhibitors and uses thereof
IL266109A (en) Tyk2 inhibitors and uses thereof
SG11201704651UA (en) Pyridazinone macrocycles as irak inhibitors and uses thereof
IL258180B (en) Heterocyclic compounds and uses thereof
ZA201801056B (en) Heteroaryl compounds as irak inhibitors and uses thereof
ZA201800975B (en) Heteroaryl compounds as irak inhibitors and uses thereof
IL291267A (en) Jak1 selective inhibitors and uses thereof
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
EP3134091A4 (en) Irak inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
SG11201706029VA (en) Anti-senescence compounds and uses thereof
ZA201801548B (en) Cyano thienotriazolodiazepines and uses thereof
SG10201911204WA (en) Autotaxin inhibitors and uses thereof
IL263949A (en) Complement inhibitors and uses thereof
IL297057B2 (en) Combinations and uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL254916A0 (en) Inhibitors and their uses
SG11201705907XA (en) Mir-92 inhibitors and uses thereof
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201504763D0 (en) Compounds and uses
IL254241A0 (en) Etv2 and uses thereof
IL253459B (en) Isoergoline compounds and uses thereof
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB2543375B (en) Compounds and their uses